PALATIN TECHNOLOGIES INC
Close on Oct 19, 2026
- Market cap
- $23.46M
- P/E (TTM)
- –
- Dividend yield
- –
About Palatin Technologies
Pharmaceutical Preparations, SIC 2834
Palatin Technologies, Inc. is a biopharmaceutical company dedicated to developing targeted therapeutics that modulate the melanocortin receptor system. The company primarily focuses on developing melanocortin receptor-4 selective agonists, including long-acting peptides and oral small molecules, to treat obesity and rare neuroendocrine conditions such as hypothalamic obesity and Prader-Willi syndrome. Additionally, Palatin develops melanocortin receptor-1 agonist products aimed at treating inflammatory and autoimmune diseases, including ocular conditions like dry eye disease, as well as ulcerative colitis and diabetic nephropathy. The company operates through a single reportable segment and collaborates with pharmaceutical partners, including Boehringer Ingelheim and Altanispac Labs, to advance and commercialize its drug candidates.
Palatin conducts its principal administrative and operational activities from Princeton, New Jersey, where its executive offices are located. The company relies on strategic partnerships and third-party contract manufacturers for research, clinical trial advancement, and production capabilities across domestic and international jurisdictions.
Summary of the business section of Palatin Technologies's latest annual report, written by StockData.
Company profile
Company
- Legal name
- PALATIN TECHNOLOGIES INC
- Headquarters
- Cranbury, NJ
- Address
- 4b Cedar Brook Drive 08512
- Phone
- (609) 495-2200
- Website
- palatin.com
- Employees
- 25, Jun 30, 2026
- Industry
- Pharmaceutical Preparations
- Incorporated in
- New Jersey
- Fiscal year ends
- June 30
- Auditor
- KPMG LLP, Philadelphia, Pennsylvania
Stock & identifiers
- Ticker
- PTN
- Exchange
- Nasdaq
- IPO date
- Oct 15, 1997
- Shares outstanding
- 2M, Sep 25, 2026
- Public float
- $25.70M, Dec 31, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-50 reverse, Sep 23, 2025; 1-for-50 reverse, Aug 12, 2025; 1-for-25 reverse, Aug 31, 2022; 1-for-10 reverse, Sep 27, 2010
- SEC CIK
- 911216
- CUSIP
- 696077601
- ISIN
- US6960776010
- LEI
- 549300IDN7TWMQI0JP93
- EIN
- 95-4078884
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Carl Spana | President and CEO, Director | 65,160 |
| Stephen T. Wills | Executive VP and CFO/COO | 63,792 |
| Arlene Morris | Director | 41,580 |
| John K. A. Prendergast | Director | 13,802 |
| Alan W. Dunton | Director | 21,601 |
| Robert K. Deveer Jr | Director | 160,125 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $738.50K | $96.06K | $687.96K | $2 | – |
| FY2024 | $1.45M | $660.99K | $1.42M | $29 | – |
| FY2023 | $1.30M | $283.92K | $1.19M | $31 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“of September 25, 2026, we employed 25 full-time employees, of whom 16 were engaged primarily in research and development activities and”
Corporate history
Events identified from SEC filings